← Leaderboards
Sunil Sudhir Raikar
Emory University
$1,320,662
Attributed
$1,518,843
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $447.7K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,518,843 · 2
By mechanism
K08$1,122,480 · 1
R21$396,363 · 1
Top collaborators
- Todd Sulchek2 shared
Most similar at Emory University
Same institution · by research overlap
- Sara Auld$4,352,467
- Brian D. Evavold$24,193,113
- Edward T Morgan$16,635,008
- Lauren Cari Fleischer$117,818
- Tracey Jane Lamb$8,710,457
Others in their field
Other Emerging Leaders on “Immunocompromised Host”
- Robert Wilson Frenck · Cincinnati Childrens Hosp Med Ctr$16,660,001
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$12,149,398
- Thomas Dick · Rbhs-New Jersey Medical School$8,498,822
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,148,261
- Christopher M Jewell · Baltimore Va Medical Center$4,979,448
- Michael Daniel Keller · Children'S Research Institute$4,910,377
Research focus
Immunocompromised HostPre-ClinicalCytotoxicityGraft Vs Host DiseaseLentivirus VectorMalignant NeoplasmsCell TherapyCytokineExperimental StudyGenetically Modified CellsIn VitroIn VivoLifeMalignant - DescriptorCell LineCellsChimeric Antigen ReceptorChimeric Antigen Receptor T CellsAntigen TargetingDesignAllogenicCar T Cell TherapyInnovationReceptor Expression
Grant awards (7)
Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia$224,496
K08 · FY2024 · CA · contact PI
Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia$224,496
K08 · FY2023 · CA · contact PI
Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia$224,496
K08 · FY2022 · CA · contact PI
Microfluidic platforms to generate 'off-the-shelf' fratricide-resistant CAR T cells for T-cell malignancies$173,201
R21 · FY2022 · CA · contact PI
Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia$224,496
K08 · FY2021 · CA · contact PI
Microfluidic platforms to generate 'off-the-shelf' fratricide-resistant CAR T cells for T-cell malignancies$223,162
R21 · FY2021 · CA · contact PI
Gamma delta T-cell immunotherapy for T-cell acute lymphoblastic leukemia$224,496
K08 · FY2020 · CA · contact PI